Dynavax Technologies Financials
| DVAX Stock | USD 12.98 0.04 0.31% |
Dynavax |
Understanding current and past Dynavax Technologies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Dynavax Technologies' financial statements are interrelated, with each one affecting the others. For example, an increase in Dynavax Technologies' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Dynavax Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dynavax Technologies. Check Dynavax Technologies' Beneish M Score to see the likelihood of Dynavax Technologies' management manipulating its earnings.
Dynavax Technologies Stock Summary
Dynavax Technologies competes with Alkermes Plc, Neurocrine Biosciences, Intracellular, Aquestive Therapeutics, and Amphastar. Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Dynavax Technologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 311 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US2681582019 |
| CUSIP | 268158201 268158102 |
| Location | California; U.S.A |
| Business Address | 2100 Powell Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.dynavax.com |
| Phone | 510 848 5100 |
| Currency | USD - US Dollar |
Dynavax Technologies Key Financial Ratios
| Return On Equity | 0.0318 | ||||
| Return On Asset | -0.0038 | ||||
| Target Price | 25.0 | ||||
| Number Of Employees | 408 | ||||
| Beta | 1.34 |
Dynavax Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Dynavax Technologies's current stock value. Our valuation model uses many indicators to compare Dynavax Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dynavax Technologies competition to find correlations between indicators driving Dynavax Technologies's intrinsic value. More Info.Dynavax Technologies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dynavax Technologies' earnings, one of the primary drivers of an investment's value.Dynavax Technologies Systematic Risk
Dynavax Technologies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Dynavax Technologies volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Dynavax Technologies correlated with the market. If Beta is less than 0 Dynavax Technologies generally moves in the opposite direction as compared to the market. If Dynavax Technologies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Dynavax Technologies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Dynavax Technologies is generally in the same direction as the market. If Beta > 1 Dynavax Technologies moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Dynavax Technologies is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Dynavax has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Dynavax Technologies' financials are consistent with your investment objective using the following steps:- Review Dynavax Technologies' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Dynavax Technologies' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Dynavax Technologies' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Dynavax Technologies' stock is overvalued or undervalued.
Dynavax Technologies Thematic Clasifications
Dynavax Technologies is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
Dynavax Technologies January 29, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Dynavax Technologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Dynavax Technologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Dynavax Technologies based on widely used predictive technical indicators. In general, we focus on analyzing Dynavax Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Dynavax Technologies's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.27 | |||
| Information Ratio | 0.0417 | |||
| Maximum Drawdown | 17.05 | |||
| Value At Risk | (2.05) | |||
| Potential Upside | 3.06 |
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.